Allison A. DiPasquale, MD

Dr. Allison DiPasquale and Dr. Sonya Reid conclude the discussion by highlighting the future of personalized care in early-stage HR-positive, HER2-negative breast cancer and the evolving role of genomic testing.

Dr. Allison DiPasquale and Dr. Sonya Reid discuss how multidisciplinary collaboration supports the integration of genomic testing into the management of early-stage HR-positive, HER2-negative breast cancer.

Dr. Sonya Reid and Dr. Allison DiPasquale discuss how treatment planning for early-stage HR-positive, HER2-negative breast cancer extends beyond genomic assay results alone by integrating clinicopathologic features and patient-specific factors.

Dr. Allison DiPasquale asks Dr. Sonya Reid how longer-term follow-up from landmark studies has influenced confidence in the use of genomic assays for early-stage HR-positive, HER2-negative breast cancer.

Dr. Sonya Reid and Dr. Allison DiPasquale discuss factors that influence the selection and application of genomic assays in the management of early-stage HR-positive, HER2-negative breast cancer.

Dr. Sonya Reid asks Dr. Allison DiPasquale how recurrence scores influence treatment recommendations and patient discussions in early-stage HR-positive, HER2-negative breast cancer.

Dr. Allison DiPasquale and Dr. Sonya Reid discuss how findings from the RxPONDER trial have influenced treatment decision-making for patients with early-stage HR-positive, HER2-negative, node-positive breast cancer.

Dr. Allison DiPasquale invites Dr. Sonya Reid to discuss the clinical impact of the landmark TAILORx trial on the management of early-stage HR-positive, HER2-negative, node-negative breast cancer.

Dr. Allison DiPasquale and Dr. Sonya Reid discuss the advantages and limitations of performing genomic testing on biopsy specimens versus final surgical pathology in early-stage HR-positive, HER2-negative breast cancer.

Dr. Sonya Reid and Dr. Allison DiPasquale discuss how clinical practice guidelines have influenced the use of genomic testing in the management of early-stage HR-positive, HER2-negative breast cancer.

Dr. Sonya Reid invites Dr. Allison DiPasquale to discuss how genomic testing is incorporated into the clinical workflow for patients with early-stage HR-positive, HER2-negative breast cancer.

Dr. Sonya Reid introduces the program by outlining the objectives of the discussion, which focus on the expanding role of genomic testing in the management of early-stage HR-positive, HER2-negative breast cancer.

Allison A. DiPasquale, MD, discusses the continued evaluation of Cerianna positron emission tomography scans in patients with breast cancer and highlights the need for a multidisciplinary approach when treating patients in this population.